

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

216354Orig1s000

Trade Name: Austedo XR

Generic or Proper Name: Deutetrabenazine extended release

Sponsor: Teva Neuroscience, Inc.

Approval Date: February 17th, 2023

Indication: Treatment of chorea associated with Huntington's disease and tardive dyskinesia.

CENTER FOR DRUG EVALUATION AND RESEARCH

216354Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	
Clinical Review(s)	X
Product Quality Review(s)	X
Non-Clinical Review(s)	
Statistical Review(s)	
Clinical Microbiology / Virology Review(s)	
Clinical Pharmacology Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

216354Orig1s000

APPROVAL LETTER



NDA 216354

NDA APPROVAL

Teva Neuroscience, Inc.
Attention: Randy Thear, MBA
Associate Director, Global Regulatory Affairs
145 Brandywine Parkway
West Chester, PA 19380

Dear Mr. Thear:

Please refer to your new drug application (NDA) dated April 21, 2022, received April 21, 2022, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Austedo XR (deutetrabenazine extended-release) 6, 12, and 24 mg tablets.

This NDA provides for the use of Austedo XR (deutetrabenazine extended-release) 6, 12, and 24 mg tablets for the treatment of chorea associated with Huntington's disease and tardive dyskinesia.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible via publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

CARTON AND CONTAINER LABELING

Submit final printed carton and container labeling that are identical to the clean versions of carton and container labeling submitted on February 15, 2023, as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission **“Final Printed Carton and Container Labeling for approved NDA 216354.”** Approval of this submission by FDA is not required before the labeling is used.

DATING PERIOD

Based on the stability data submitted to date, the expiry dating period for Austedo XR (deutetrabenazine extended-release) 6, 12, and 24 mg tablets shall be as stated below based on the dosage strength and packaging types when stored at controlled room temperature, 20°C to 25°C:

- 6 mg tablets in 30-count bottles: 18 months
- 12 mg and 24 mg tablets in 30-count bottles: 24 months
- 6 mg, 12 mg, and 24 mg tablets in blister packs: 18 months

Results of ongoing stability should be submitted throughout the dating period in your annual report, as they become available, including the results of stability studies from the first three production lots of each strength and primary container.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

- Because deutetrabenazine (Austedo, SD-809/TEV 50717) has been granted orphan drug designation for the treatment of chorea associated with Huntington’s disease, you are exempt from this requirement for this indication.
- For the treatment of tardive dyskinesia, we are waiving the pediatric study requirement for this application because the necessary studies are impossible or highly impracticable because the condition is rare in pediatric patients.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the

U.S. Food and Drug Administration
Silver Spring, MD 20993
www.fda.gov

final guidance for industry *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.³

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.⁴ Information and Instructions for completing the form can be found at FDA.gov.⁵

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please contact Stacy Metz, PharmD, Senior Regulatory Project Manager, at stacy.metz@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Teresa Buracchio, MD
Director
Division of Neurology 1
Office of Neuroscience
Center for Drug Evaluation and Research

ENCLOSURE(S):

- Content of Labeling
 - Prescribing Information
 - Medication Guide

³ For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

⁴ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

⁵ <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TERESA J BURACCHIO
02/17/2023 12:43:56 PM